Identificador persistente para citar o vincular este elemento:
http://hdl.handle.net/10553/52045
Campo DC | Valor | idioma |
---|---|---|
dc.contributor.author | Pérez, Antonio | en_US |
dc.contributor.author | Wägner, Ana Maria | en_US |
dc.contributor.author | Carreras, Gemma | en_US |
dc.contributor.author | Giménez, Gabriel | en_US |
dc.contributor.author | Sánchez-Quesada, Jose Luis | en_US |
dc.contributor.author | Rigla, Mercedes | en_US |
dc.contributor.author | Gómez-Gerique, Juan Antonio | en_US |
dc.contributor.author | Pou, Jose Maria | en_US |
dc.contributor.author | De Leiva, Alberto | en_US |
dc.date.accessioned | 2018-11-25T16:59:02Z | - |
dc.date.available | 2018-11-25T16:59:02Z | - |
dc.date.issued | 2000 | en_US |
dc.identifier.issn | 0003-9926 | en_US |
dc.identifier.uri | http://hdl.handle.net/10553/52045 | - |
dc.description.abstract | Background Data on the prevalence of dyslipidemia in type 1 diabetes mellitus are scarce and are based on total triglyceride and total cholesterol concentrations alone. Objective To assess the effect of glycemic optimization on the prevalence of dyslipidemia and low-density lipoprotein cholesterol (LDL-C) concentrations requiring intervention in patients with type 1 diabetes. Patients A total of 334 adults with type 1 diabetes and 803 nondiabetic control subjects. Methods Levels of glycosylated hemoglobin, total cholesterol, total triglyceride, high-density lipoprotein cholesterol (HDL-C), and LDL-C were assessed at baseline and after 3 to 6 months of intensive therapy with multiple insulin doses. Results Levels of LDL-C greater than 4.13 mmol/L (>160 mg/dL) and total triglyceride greater than 2.25 mmol/L (>200 mg/dL) and low HDL-C levels (<0.9 mmol/L [<35 mg/dL] in men or <1.1 mmol/L [<45 mg/dL] in women) were found in 16%, 5%, and 20% of patients and 13%, 6%, and 9% of controls, respectively (P<.001 for HDL-C). Diabetic women showed more hypercholesterolemia than nondiabetic women (15.6% vs 8.5%; P = .04). After glycemic optimization (mean ± SD glycosylated hemoglobin decrease, 2.2 ± 1.96 percentage points), the prevalence of LDL-C levels greater than 4.13 mmol/L (>160 mg/dL) became lower in diabetic men than in nondiabetic men (9.7% vs 17.5%; P = .04), but women showed frequencies of dyslipidemia similar to their nondiabetic counterparts. The proportion of patients with LDL-C concentrations requiring lifestyle (>2.6 mmol/L [>100 mg/dL]) or drug (>3.4 mmol/L [>130 mg/dL]) intervention decreased from 78% and 42% to 66% and 26%, respectively. Conclusions Low HDL-C is the most frequent dyslipidemic disorder in patients with poorly controlled insulin-treated type 1 diabetes, and a high proportion show LDL-C levels requiring intervention. Less favorable lipid profiles could explain the absence of sex protection in diabetic women. The improvement caused by glycemic optimization puts forward intensive therapy as the initial treatment of choice for dyslipidemia in poorly controlled type 1 diabetes. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Archives of internal medicine (1960) | en_US |
dc.source | Archives of Internal Medicine[ISSN 0003-9926],v. 160(18), p. 2756-2762 (Octubre 2000) | en_US |
dc.subject | 32 Ciencias médicas | en_US |
dc.subject | 3205 Medicina interna | en_US |
dc.subject | 320502 Endocrinología | en_US |
dc.subject.other | Dyslipidemia | en_US |
dc.subject.other | Diabetes mellitus | en_US |
dc.subject.other | Glycosylated hemoglobin | en_US |
dc.subject.other | Cholesterol | en_US |
dc.subject.other | Lipoprotein | en_US |
dc.title | Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus: Effect of glycemic control | en_US |
dc.type | info:eu-repo/semantics/article | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1001/archinte.160.18.2756 | en_US |
dc.identifier.scopus | 0034626386 | - |
dc.contributor.authorscopusid | 7402509742 | - |
dc.contributor.authorscopusid | 7401456520 | - |
dc.contributor.authorscopusid | 6603602740 | - |
dc.contributor.authorscopusid | 23970533700 | - |
dc.contributor.authorscopusid | 6603877734 | - |
dc.contributor.authorscopusid | 6603627533 | - |
dc.contributor.authorscopusid | 7003411647 | - |
dc.contributor.authorscopusid | 14322294200 | - |
dc.contributor.authorscopusid | 7005846734 | - |
dc.description.lastpage | 2762 | en_US |
dc.identifier.issue | 18 | - |
dc.description.firstpage | 2756 | en_US |
dc.relation.volume | 160 | en_US |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo | en_US |
dc.description.numberofpages | 7 | en_US |
dc.utils.revision | Sí | en_US |
dc.date.coverdate | Octubre 2000 | en_US |
dc.identifier.ulpgc | Sí | en_US |
dc.contributor.buulpgc | BU-MED | en_US |
dc.description.jcr | 6,055 | - |
dc.description.jcrq | Q1 | - |
item.grantfulltext | none | - |
item.fulltext | Sin texto completo | - |
crisitem.author.dept | GIR IUIBS: Diabetes y endocrinología aplicada | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
crisitem.author.orcid | 0000-0002-7663-9308 | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.fullName | Wägner, Anna Maria Claudia | - |
Colección: | Artículos |
Citas SCOPUSTM
62
actualizado el 17-nov-2024
Citas de WEB OF SCIENCETM
Citations
57
actualizado el 17-nov-2024
Visitas
34
actualizado el 10-feb-2024
Google ScholarTM
Verifica
Altmetric
Comparte
Exporta metadatos
Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.